Coram appoints Amaral president and CEO; Caremark countersuit seeks $100 mil.
CORAM APPOINTS AMARAL PRESIDENT AND CEO to succeed James Sweeney, who has served as CEO since July 1994 and as interim president since August, when former President Patrick Fortune resigned. The alternate site patient care provider announced the appointment Oct. 16. Donald Amaral comes to Coram from the health services provider OrNda Healthcorp, where he was president and chief operating officer. Sweeney will continue as chairman of Coram's board of directors.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth